Comparative Pharmacology
Head-to-head clinical analysis: ACCRETROPIN versus SEROSTIM LQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCRETROPIN versus SEROSTIM LQ.
ACCRETROPIN vs SEROSTIM LQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human growth hormone that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathway leading to increased IGF-1 production and growth-promoting effects.
Recombinant human growth hormone (somatropin) that binds to growth hormone receptors, activating JAK-STAT signaling pathways, leading to increased insulin-like growth factor-1 (IGF-1) production, which promotes linear growth and anabolic effects.
IM: 0.1 mg/kg three times per week; SC: 0.1 mg/kg three times per week.
0.2 mg/kg subcutaneously once daily for 4 weeks in HIV-associated wasting; for growth hormone deficiency, 0.005 mg/kg subcutaneously once daily initially, titrated to 0.01 mg/kg once daily.
None Documented
None Documented
Terminal elimination half-life: 4.5 hours (clinical context: supports twice-daily dosing)
2.6 hours (subcutaneous administration); terminal half-life is approximately 2-3 hours, requiring daily dosing for growth hormone deficiency.
Renal excretion: 70% as intact drug; biliary/fecal: 30% as metabolites
Renal: >90% of somatropin is metabolized in the liver and kidneys; less than 1% of the administered dose is excreted unchanged in urine.
Category C
Category C
Growth Hormone
Growth Hormone